Department of Endodontics, Stomatological Hospital, Southern Medical University, Guangzhou, Guangdong, China; School of Stomatology, Southern Medical University, Guangzhou, Guangdong, China.
Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
Dent Mater. 2023 Mar;39(3):260-274. doi: 10.1016/j.dental.2023.01.006. Epub 2023 Jan 27.
Treating dental hypersensitivity (DH) rapidly and maintaining long-term effectiveness remains challenging. We aimed to address this problem by fabricating a novel rapidly mineralized biphasic calcium phosphate (RMBCP), which could rapidly elicit mineralization to form hydroxyapatite (HA) and perform excellent acid-resistant stability, thus effectively blocking the exposed dental tubules and protecting them from acid attack.
RMBCP was firstly synthesized by precisely adjusting the molar ratio of acetic acid and calcium hydroxide and characterized by X-ray diffraction (XRD), X-ray fluorescence microprobe (XRF), Fourier-transform infrared (FTIR) spectrometer, scanning electron microscope (SEM), and transmission electron microscope (TEM). Subsequently, using a commercialized desensitizing agent, 45S5 bioglass (BG), as the control group, the mineralization performance of RMBCP was investigated in simulated body fluid (SBF), Dulbecco's modified eagle medium (DMEM), and even slightly acidic artificial saliva (pH=6.6). Moreover, the biocompatibility of RMBCP was studied. Finally, the tubule occlusion effect and acid-resistant stability of RMBCP were evaluated in vitro and in vivo.
The rapid mineralization behavior of RMBCP could easily adhere to the dentin surface and block the dentinal tubules completely in vitro and in vivo within 7days. RMBCP performed high acid-resistant stability to maintain the long-term therapeutic effect of DH treatment.
Developing novel bioactive calcium phosphate materials with the ability to trigger mineralization for HA formation rapidly will be an effective strategy for the long-term treatment of dentin hypersensitivity.
快速治疗牙本质敏感症（DH）并保持长期疗效仍然具有挑战性。我们旨在通过制造新型快速矿化双相磷酸钙（RMBCP）来解决这个问题，该材料能够迅速引发矿化形成羟基磷灰石（HA），并具有优异的耐酸稳定性，从而有效阻塞暴露的牙本质小管，防止其受到酸的侵蚀。
通过精确调整醋酸和氢氧化钙的摩尔比，首次合成了 RMBCP，并通过 X 射线衍射（XRD）、X 射线荧光微探针（XRF）、傅里叶变换红外（FTIR）光谱仪、扫描电子显微镜（SEM）和透射电子显微镜（TEM）对其进行了表征。随后，使用商业化的脱敏剂 45S5 生物玻璃（BG）作为对照组，在模拟体液（SBF）、杜氏改良伊格尔培养基（DMEM）甚至稍酸性人工唾液（pH=6.6）中研究了 RMBCP 的矿化性能。此外，还研究了 RMBCP 的生物相容性。最后，在体外和体内评估了 RMBCP 的管腔闭塞效果和耐酸稳定性。
RMBCP 的快速矿化行为能够在体外和体内 7 天内轻松附着在牙本质表面并完全阻塞牙本质小管。RMBCP 具有较高的耐酸稳定性，能够维持 DH 治疗的长期疗效。
开发具有快速诱导 HA 形成矿化能力的新型生物活性钙磷材料将是长期治疗牙本质敏感症的有效策略。
